Send to

Choose Destination
See comment in PubMed Commons below
Vaccine. 2010 Jun 17;28(27):4394-401. doi: 10.1016/j.vaccine.2010.04.048. Epub 2010 Apr 29.

Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector.

Author information

  • 1Central Veterinary Institute of Wageningen University Research Centre, AB Lelystad, The Netherlands.


Rift Valley fever virus (RVFV) causes recurrent large outbreaks among humans and livestock. Although the virus is currently confined to the African continent and the Arabian Peninsula, there is a growing concern for RVFV incursions into countries with immunologically naïve populations. The RVFV structural glycoproteins Gn and Gc are preferred targets in the development of subunit vaccines that can be used to control future outbreaks. We here report the production of Gn and Gc by a recombinant vaccine strain of the avian paramyxovirus Newcastle disease virus (NDV) and demonstrate that intramuscular vaccination with this experimental NDV-based vector vaccine provides complete protection in mice. We also demonstrate that a single intramuscular vaccination of lambs, the main target species of RVFV, is sufficient to elicit a neutralizing antibody response.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center